Kala Bio (KALA) Short term Debt (2016 - 2025)
Kala Bio (KALA) posted Short term Debt of $28.4 million for Q3 2025, up 198.72% sequentially from $9.5 million in Q2 2025, and up 58.04% YoY from $18.0 million in Q3 2024.
Kala Bio (KALA) Short term Debt (2016 - 2025) Analysis & Trends
Kala Bio has reported Short term Debt for 7 years, with the latest figure at $28.4 million in Q3 2025.
- Quarterly Short term Debt rose 58.04% year-over-year to $28.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $28.4 million (up 58.04% YoY) and the FY2024 annual result came in at $10.3 million, changed N/A from the prior year.
- Short term Debt improved to $28.4 million in Q3 2025 per KALA's latest filing, from $9.5 million in the prior quarter.
- Over five years, Short term Debt peaked at $28.4 million in Q3 2025 and troughed at $3.7 million in Q1 2022.
- A 4-year average of $9.9 million and a median of $7.8 million in 2024 frame the typical range for Short term Debt.
- The widest YoY moves for Short term Debt: up 158.73% in 2025, down 20.64% in 2025.
- Over 4 years, Short term Debt stood at $3.8 million in 2021, then rose by 8.62% to $4.1 million in 2022, then jumped by 149.3% to $10.3 million in 2024, then surged by 174.87% to $28.4 million in 2025.
- According to Business Quant data, Short term Debt over the past three periods registered $28.4 million, $9.5 million, and $15.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Kala Bio | 9.97 Mn | 9.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 28.41 Mn |
| Jun 30, 2025 | 9.51 Mn |
| Mar 31, 2025 | 15.50 Mn |
| Dec 31, 2024 | 10.34 Mn |
| Sep 30, 2024 | 17.98 Mn |
| Jun 30, 2024 | 11.99 Mn |
| Mar 31, 2024 | 5.99 Mn |
| Dec 31, 2022 | 4.15 Mn |
| Sep 30, 2022 | 3.92 Mn |
| Jun 30, 2022 | 3.77 Mn |
| Mar 31, 2022 | 3.67 Mn |
| Dec 31, 2021 | 3.82 Mn |
| Sep 30, 2018 | 3.33 Mn |
| Jun 30, 2018 | 1.67 Mn |
| Dec 31, 2017 | 6.67 Mn |
| Sep 30, 2017 | 6.11 Mn |
| Jun 30, 2017 | 2.22 Mn |
| Dec 31, 2016 | 556,000.00 |